Nuvilex, Inc. Reaches Unofficial Starting Line of Its Phase 3 Pancreatic Cancer Clinical Trials NEW YORK, NY--(Marketwired - Nov 5, 2013) - Nuvilex, Inc. (OTCQB: NVLX) made an announcement yesterday that should have investors excited that the company's Phase 3 clinical trials may have...

Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics SILVER SPRING, MD--(Marketwired - Nov 4, 2013) - Nuvilex, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases,...

Nuvilex, Inc. Enters Most Important Step of Phase III Trials Outside of Patient Enrollment NEW YORK, NY--(Marketwired - Oct 1, 2013) - When Nuvilex, Inc. (OTCQB: NVLX) announced that it had contracted Inno Biologics to generate cell clones that will be the basis of the company's future...